Sale
  • Immunofluorescence analysis of paraformaldehyde fixed MCF7 cells,  permeabilized with 0.15% Triton. Primary incubation 1hr (1:100 dilution) followed by Alexa Fluor® 488 secondary antibody (1:1000 dilution), showing cytoplasmic staining. The nuclear stain is DAPI (blue). Negative control: Mouse IgG1 negative control followed by Alexa Fluor® 488 secondary antibody.
  • (0.1µg/ml) staining in MCF7 cells lysate (35µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.
  •  Immunofluorescence - Anti-HEF1 Antibody [2G9]
  • Immunofluorescence analysis of paraformaldehyde fixed MCF7 cells,  permeabilized with 0.15% Triton. Primary incubation 1hr (1:100 dilution) followed by Alexa Fluor® 488 secondary antibody (1:1000 dilution), showing cytoplasmic staining. The nuclear stain is DAPI (blue). Negative control: Mouse IgG1 negative control followed by Alexa Fluor® 488 secondary antibody
  • Immunofluorescence staining of MDA-MB231 cells with the 2G9 antibody at a 1/200 dilution. Cells were fixed in 3.8% PFA for 10 minutes, and staining was performed for 1 hour at room temperature.
  • IHC staining of Formalin/PFA-fixed paraffin-embedded sections using the Anti-HEF1 antibody [2G9]. Normal breast tissue is shown on the left, and ductal carcinoma on the right. The antibody was used at 1/100, diluted in TBS with 0.1% Tween20 and 3% BSA, with o/night incubation.

Current Image Legend:




HEF1/NEDD-9 Monoclonal Antibody [2G9]

Catalogue Number: IQ296

Catalogue Number: IQ297

Catalogue Number: IQ297AF

Item in Stock Secure Online Payments

If you have any questions or require further information, please contact us and one of our scientists will be in touch.

A free sample may be available. Please click here to request this.

  • £265.10

Datasheet

Download Variant Datasheet
Primary Description: Mouse Anti-HEF1/NEDD-9 [2G9]
Primary Description: Mouse Anti-HEF1/NEDD-9 [2G9]
Primary Description: HEF1/NEDD-9 Antibody [2G9]- BSA/Azide Free
Target Antigen: HEF1
Target Antigen: HEF1
Target Antigen: HEF1
Catalogue Number: IQ296
Catalogue Number: IQ297
Catalogue Number: IQ297AF
Quantity: 50ul
Quantity: 0.1ml
Quantity: 0.05mg
Concentration: 1mg/ml
Concentration: 1mg/ml
Concentration: 1mg/ml
Clone: 2G9
Clone: 2G9
Clone: 2G9
Host: Mouse
Host: Mouse
Host: Mouse
Isotype: IgG1 kappa
Isotype: IgG1 kappa
Isotype: IgG1 kappa
Myeloma/Fusion Partners: SP2/0
Myeloma/Fusion Partners: SP2/0
Myeloma/Fusion Partners: SP2/O
Immunogen: GST-HEF-1(82-398aa)
Immunogen: GST-HEF-1(82-398aa)
Immunogen: GST-HEF-1(82-398aa)
Species Reactivity: Mouse, Rat, Human
Species Reactivity: Mouse, Rat, Human
Species Reactivity: Mouse, Rat, Human
Purification: Protein G
Purification: Protein G
Purification: Protein G
Format: Purified antibody containing PBS 0.1% sodium azide;
Format: Purified antibody containing PBS 0.1% sodium azide;
Format: Purified antibody containing PBS. Does not contain sodium azide or BSA
Applications: WB, ICC/IF, IHC (Human Kidney)
Applications: WB, ICC/IF, IHC (Human Kidney)
Applications: WB, ICC/IF, IHC (Human Kidney)
Dilutions: Optimal antibody dilution should be determined by titration, however as a guideline try: WB 0.1µg/ml, IF 1:100
Dilutions: Optimal antibody dilution should be determined by titration, however as a guideline try: WB 0.1µg/ml, IF 1:100
Dilutions: Optimal antibody dilution should be determined by titration, however as a guideline try: WB 0.1µg/ml, IF 1:100
Also Known As: HEF1 (Cas-L); CASL; dJ49G10.2; dJ761I2.1; NEDD9; NEDD9 protein; NY REN 12 antigen; p105; Protein NEDD9;
Also Known As: HEF1 (Cas-L); CASL; dJ49G10.2; dJ761I2.1; NEDD9; NEDD9 protein; NY REN 12 antigen; p105; Protein NEDD9;
Also Known As: HEF1 (Cas-L); CASL; dJ49G10.2; dJ761I2.1; NEDD9; NEDD9 protein; NY REN 12 antigen; p105; Protein NEDD9;
Pubmed ID(s): 30267961, 23874939, 30579603, 31801619, 29773902, 30538176, 29519561, 28194179, 29084958, 29371931, 26893853, 27033521, 27805249, 25812772, 24514042, 24058594, 22328516, 22665056, 21829474, 19587023, 19464348, 19376971, 18282814, 16814714, 23037767, 22061964, 22509381, 21317929, 21145356, 19539609, 19648964, 16288224, 16344118, 11438665,
Pubmed ID(s): 30267961, 23874939, 30579603, 31801619, 29773902, 30538176, 29519561, 28194179, 29084958, 29371931, 26893853, 27033521, 27805249, 25812772, 24514042, 24058594, 22328516, 22665056, 21829474, 19587023, 19464348, 19376971, 18282814, 16814714, 23037767, 22061964, 22509381, 21317929, 21145356, 19539609, 19648964, 16288224, 16344118, 11438665
Pubmed ID(s): 30267961, 23874939, 30579603, 31801619, 29773902, 30538176, 29519561, 28194179, 29084958, 29371931, 26893853, 27033521, 27805249, 25812772, 24514042, 24058594, 22328516, 22665056, 21829474, 19587023, 19464348, 19376971, 18282814, 16814714, 23037767, 22061964, 22509381, 21317929, 21145356, 19539609, 19648964, 16288224, 16344118, 11438665
Entrez Gene ID(s): 4739, 18003, 291044
Entrez Gene ID(s): 4739, 18003, 291044
Entrez Gene ID(s): 4739, 18003, 291044
SwissProt ID(s): Q14511, O35177
SwissProt ID(s): Q14511, O35177
SwissProt ID(s): Q14511, O35177
Omim ID(s): 602265
Omim ID(s): 602265
Omim ID(s): 602265

Citations

Citation Count: 34
Citations:

Wang Y et al. ZMYND10, an epigenetically regulated tumor suppressor, exerts tumor-suppressive functions via miR145-5p/NEDD9 axis in breast cancer. Clin Epigenetics 11:184 (2019).
View Source


Zhang C et al. HEF1 regulates differentiation through the Wnt5a/ß-catenin signaling pathway in human gastric cancer. Biochem Biophys Res Commun 509:201-208 (2019).
View Source


Semelakova M et al. Vimentin and Non-Muscle Myosin IIA are Members of the Neural Precursor Cell Expressed Developmentally Down-Regulated 9 (NEDD9) Interactome in Head and Neck Squamous Cell Carcinoma Cells. Transl Oncol 12:49-61 (2019).
View Source


Roy NH et al. Crk adaptor proteins mediate actin-dependent T cell migration and mechanosensing induced by the integrin LFA-1. Sci Signal 11:N/A (2018).PubMed: 30538176El-Babouly IM et al. The role of neural precursor cell-expressed developmentally down-regulated protein 9 in predicting bacillus Calmette-Guerin response in nonmuscle invasive bladder cancer. Urol Oncol 36:242.e9-242.e14 (2018). IHC-P .
View Source


Gabbasov R et al. NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice. Oncogene 37:4854-4870 (2018).
View Source


Harb OA et al. The Prognostic Role of NEDD9 and P38 Protein Expression Levels in Urinary Bladder Transitional Cell Carcinoma. J Oncol 2017:6095205 (2017). IHC-P ; Human .
View Source


Waheed S et al. Progesterone and calcitriol reduce invasive potential of endometrial cancer cells by targeting ARF6, NEDD9 and MT1-MMP. Oncotarget 8:113583-113597 (2017). WB ; Human .
View Source


Liu JA et al. Asymmetric localization of DLC1 defines avian trunk neural crest polarity for directional delamination and migration. Nat Commun 8:1185 (2017).
View Source


Kim JH et al. Genome-wide screen identifies novel machineries required for both ciliogenesis and cell cycle arrest upon serum starvation. Biochim Biophys Acta 1863:1307-18 (2016).PubMed: 27033521Gao ZF et al. Tumor-suppressive role of HACE1 in hepatocellular carcinoma and its clinical significance. Oncol Rep 36:3427-3435 (2016).
View Source


Li M et al. High expression of HEF1 predicts a poorer prognosis of hepatocellular carcinoma: A retrospective study. Mol Clin Oncol 4:159-165 (2016).
View Source


Lu P et al. Expression of NEDD9 in hepatocellular carcinoma and its clinical significance. Oncol Rep 33:2375-83 (2015).PubMed: 25812772Domingues MJ et al. ß-catenin inhibitor ICAT modulates the invasive motility of melanoma cells. Cancer Res 74:1983-95 (2014). Human .
View Source


Sima N et al. The Overexpression of Scaffolding Protein NEDD9 Promotes Migration and Invasion in Cervical Cancer via Tyrosine Phosphorylated FAK and SRC. PLoS One 8:e74594 (2013). IHC ; Human .
View Source


Kondo S et al. Impact of the integrin signaling adaptor protein NEDD9 on prognosis and metastatic behavior of human lung cancer. Clin Cancer Res. 2012 Nov 15;18(22):6326-38. doi: 10.1158/1078-0432.CCR-11-2162. Epub 2012 Oct 4. WB ; Human
View Source


The aryl hydrocarbon receptor regulates focal adhesion sites through a non-genomic FAK/Src pathway. Tomkiewicz C et al. Oncogene. 2012 Jun 4. doi: 10.1038/onc.2012.197. [Epub ahead of print]
View Source


NEDD9 stabilizes focal adhesions, increases binding to the extra-cellular matrix and differentially effects 2D versus 3D cell migration. Zhong J et al. PLoS One. 2012;7(4):e35058. doi: 10.1371/journal.pone.0035058. Epub 2012 Apr 11
View Source


Bradbury P et al. PP2A phosphatase suppresses function of the mesenchymal invasion regulator NEDD9. Biochim Biophys Acta. 2012 Feb;1823(2):290-7. doi: 10.1016/j.bbamcr.2011.10.011. Epub 2011 Oct 28. IP WB ; Human
View Source


Ahn J et al. The metastasis gene NEDD9 product acts through integrin ß3 and Src to promote mesenchymal motility and inhibit amoeboid motility. J Cell Sci 125:1814-26 (2012).
View Source


Tomkiewicz C et al. The aryl hydrocarbon receptor regulates focal adhesion sites through a non-genomic FAK/Src pathway. Oncogene : (2012).
View Source


Bruna A et al. TGFß induces the formation of tumour-initiating cells in claudinlow breast cancer. Nat Commun 3:1055 (2012). WB .
View Source


Li Y et al. HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression. Oncogene. 2011 Jun 9;30(23):2633-43. doi: 10.1038/onc.2010.632. Epub 2011 Feb 14. ICC/IF IHC WB ; Human, Mouse
View Source


Kong C et al. NEDD9 Is a Positive Regulator of Epithelial-Mesenchymal Transition and Promotes Invasion in Aggressive Breast Cancer. PLoS One 6:e22666 (2011). WB ; Human .
View Source


Bradshaw LN et al. Estradiol stabilizes the 105-kDa phospho-form of the adhesion docking protein NEDD9 and suppresses NEDD9-dependent cell spreading in breast cancer cells. Biochim Biophys Acta. 2011 Feb;1813(2):340-5. doi: 10.1016/j.bbamcr.2010.11.018. Epub 2010 Dec 8. WB ; Human
View Source


Vogel T et al. Transforming growth factor beta promotes neuronal cell fate of mouse cortical and hippocampal progenitors in vitro and in vivo: identification of Nedd9 as an essential signaling component. Cereb Cortex 20:661-71 (2010). ICC/IF ; Mouse .
View Source


Nedd9/Hef1/Cas-L mediates the effects of environmental pollutants on cell migration and plasticity. Bui LC et al. Oncogene. 2009 Oct 15;28(41):3642-51. doi: 10.1038/onc.2009.224. Epub 2009 Aug 3.  ICC/IF WB ; Human
View Source


Hivert V et al. Phosphorylation of human enhancer of filamentation (HEF1) on serine 369 induces its proteasomal degradation. Biochem Pharmacol. 2009 Oct 15;78(8):1017-25. doi: 10.1016/j.bcp.2009.06.005. Epub 2009 Jun 17. WB ; Human
View Source


Aquino JB et al. The retinoic acid inducible Cas-family signaling protein Nedd9 regulates neural crest cell migration by modulating adhesion and actin dynamics. Neuroscience 162:1106-19 (2009). IHC-Fr ; Mouse,Chicken .
View Source


Zheng P & Dean J Role of Filia, a maternal effect gene, in maintaining euploidy during cleavage-stage mouse embryogenesis. Proc Natl Acad Sci U S A 106:7473-8 (2009). ICC/IF ; Mouse .
View Source


Aquino JB et al. Differential expression and dynamic changes of murine NEDD9 in progenitor cells of diverse tissues. Gene Expr Patterns 8:217-26 (2008).
View Source


Sanz-Moreno V et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell 135:510-23 (2008). IP, WB .
View Source


Natarajan M et al. HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells.Oncogene. 2006 Mar 16;25(12):1721-32. ICC/IF IP WB ; Human
View Source


Kim M et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125:1269-81 (2006).
View Source


Bargon SD et al. The Cas family docking protein, HEF1, promotes the formation of neurite-like membrane extensions. Biochim Biophys Acta. 2005 Dec 15;1746(2):143-54. Epub 2005 Nov 14. ICC/IF WB ; Human, Rat
View Source


Proteolysis of the docking protein HEF1 and implications for focal adhesion dynamics. ONeill GM ( Molecular and Cellular Biology,Aug 2001)
View Source


Protocols

Immunofluorescence protocol - Formaldehyde fixation
  1. Collect cells from T.c.unit and remove media from petri dish using suction.
  2. Wash with 1x PBS and remove.
  3. Incubate cells in pre-warm (37°C) Para-Formaldehyde for 12 minutes at room temperature on an orbital shaker.
  4. Remove PFA and incubate in 0.5% Triton X-IOO in 1x PBS for 5 minutes at room temperature.
  5. Prepare blocking reagent, this is also the antibody diluent.
  6. Wash cells 2x with 1x PBS at room temperature, for 4 minutes/wash on an orbital shaker.
  7. Block with 1 % NCS and 1x PBS for 30 minutes at room temperature.
  8. Prepare primary antibodies (50?l/coverslip) and moist staining chambers.
  9. Wash cells 2x with lx PBS at room temperature and air dry briefly.
  10. Incubate with primary antibody for 1 hr at room temperature in the dark in staining chambers. During this time prepare the secondary antibody.
  11. Wash cells 5x with 1x PBS (5 beaker changes/5 counts in each beaker)
  12. Incubate with secondary antibody for 1 hour at room temperature in the dark in staining chambers.
  13. Wash cells 5x with 1x PBS.
  14. Mount in Dapi.

Solutions (prepare fresh the same day of staining).

  • * 1x Phosphate buffered saline.
  • * Blocking reagent: 1% NCS in 1x PBS (use fresh l0x PBS).
  • * Fixation solution: 3.5% Para formaldehyde.

1.75g PFA in 20 ml d.H20 plus 5 drops 1M NaOH. Stir on a hot plate at 50-60°C until dissolved. Add 4 drops IN HCI and check pH indicator strip. PH should be 7.4. Complete volume with d.H20 to 25ml and add 25ml 2xPBS. Check pH before adding to cover slips.

Immunofluorescence protocol - Methanol/acetone fixation
  1. Collect cells from T.C.unit and remove media from petri dish using suction.
  2. Wash with 1x PBS and remove.
  3. Fix cells with cold methanol: acetone 1: 1 for 10 minutes on ice.
  4. Prepare blocking reagent, this is also the diluent for the antibodies.
  5. Remove fixative and wash cells 3x with Ix PBS at RT, for 4 minutes/wash on orbital shaker.
  6. Block with 1% NCS and Ix PBS for 30 minutes at RT.
  7. Prepare primary antibodies (50?l/coverslip) and moist staining chambers.
  8. Wash cells 2x with 1 x PBS at RT and air dry for approximately 7 minutes.
  9. Incubate with primary antibody for 1 hr at RT in the dark in staining chambers. During this time prepare secondary antibody.
  10. Wash cells 5x with 1x PBS (5 beaker changes/5 counts in each beaker)
  11. Incubate with secondary antibody for 1 hr at R T in the dark in staining chambers.
  12. Wash cells 5x with 1x PBS.
  13. Mount in Dapi.

Solutions (prepare fresh the same day of staining)

  • * 1x Phosphate buffered saline.
  • * Blocking reagent: 1% NCS in 1x PBS (use fresh 10x PBS).
  • * Fixation solution: methanol:acetone 1: 1 ice cold.
Western Blotting Protocol
  1. Transfer gel to PDVF or nitrocellulose membrane
  2. Place membrane in plastic tray in blocking buffer for one hour with agitation
  3. Rinse in wash buffer
  4. Incubate in wash buffer plus primary antibody for one hour
  5. Wash 6 X 5 minutes with wash buffer
  6. Incubate in wash buffer plus secondary antibody for one hour
  7. Wash 6X 5 minutes with wash buffer
  8. Detect (e.g. ECL, Amersham according to manufacturers instructions)
Wash buffer

PBS + 0.1% Tween 20

Blocking buffer

Wash buffer + 5% dried milk powder

The concentration of antibodies used depends on each antibody, the amount of antigen and the detection method used. Generally, dilution is in the range of a few hundred times dilution to a few thousand times dilution, but usually has to be determined empirically.

FAQ's

How do I place an order?

When placing an order we require a purchase order number, plus name and contact details of the purchaser, and the person who will be using the product. We will add VAT for every order received from an EU country, unless you are VAT exempt. For such VAT exempt customers we will need to receive a copy of the exemption certificate with the order.

Orders can be placed either by our website, via email or by mail. Please see our contact us page for more details

All orders are subject to availability. Prices of products do not include shipping, VAT or import duties, where these are applicable. Price and other information provided are subject to change without notice. While every effort is made to keep information provided Up to date, ImmuQuest will not be liable if errors should occur in such information.

Formal acceptance of an order will take place when the goods are dispatched. If prices should be changed between the time of receipt of an order and dispatch, ImmuQuest will contact you in advance.

Ordering via the website

To order via the website you will need to find the product(s) you are looking for by either using our search, browsing our categories or using our full antibody catalogue.

Once you have found the antibodies you are looking for you can view more detailed information about a specific antibody by clicking the product or the 'View' button. Once you are sure it is the antibody you are looking for you can add it to your order by clicking the 'Add To Order' button.

This places the antibody in your order basket, you can add as many antibodies as you wish. Once you have selected all of the antibodies you wish to order then click the checkout button. If you are not logged in you will be asked to login or to register, if you are logged in you will be taken to the checkout page.

On the checkout page you are able to double check your order and enter a purchase order number if you have one.

Once you are happy your order is correct you can purchase the order with debit/credit card details and your order will be submitted. Once we have received and checked your order we will contact you to arrange payment and delivery.

How long does delivery take?

Delivery usually takes no more than one week from reciept of an order.

Do you guarantee your antibodies?

Yes. Should any product not perform as described in the product literature, it will be replaced or a full refund will be given. The customer must notify ImmuQuest within 30 days after the goods have been received to request a replacement, forwarding complete test data as requested by ImmuQuest.

If items are ordered incorrectly by the customer, ImmuQuest will consider taking them back as long as they have been stored correctly and have not been opened or tampered with. Such orders may be subject to a 15% restocking charge on the items plus any shipping costs.

Requests for returns must have prior authorization from ImmuQuest, and must be made within 7 days of receipt of the items. Items must be returned in the same or equivalent packaging as originally dispatched, and by an equivalent method of delivery.

Do you charge VAT?

If you are in the EU and you are no exempt from paying VAT then we must charge VAT (charged at the prevailing UK rate).

Customers that are exempt need to fax an exemption form showing their vat exemption number.

What if I don't have a purchase order number?

You can still place an order without providing a purchase order number but we must recieve payment before your order is despatched.

Non-website orders

Non-website orders can be placed directly with Immuquest at sales@immuquest.com or click on the "contact us" tab for address details

Delivery

Offline Orders

For offline orders please call +44 (0) 1642 713533 or click here to email us.

Delivery & returns

We use federal Express for UK & international shipments, andfor standard shipments the cost is £30 UK & £55 international. If the customer uses their account, we charge a £20 handling fee (UK & international)

We are strongly committed to providing the best quality products, and the best service possible.

Should any product not perform as described in the product literature, it will be replaced or a full refund will be given. The customer must notify ImmuQuest within 30 days after the goods have been received to request a replacement, forwarding complete test data as requested by ImmuQuest.

If items are ordered incorrectly by the customer, ImmuQuest will consider taking them back as long as they have been stored correctly and have not been opened or tampered with. Such orders may be subject to a 15% restocking charge on the items plus any shipping costs.

Requests for returns must have prior authorization from ImmuQuest, and must be made within 7 days of receipt of the items. Items must be returned in the same or equivalent packaging as originally dispatched, and by an equivalent method of delivery.

Product Guarantee

We are strongly committed to providing the best quality products, and the best service possible. In order to do this we depend on your feedback.

Should any product not perform as described in the product literature, it will be replaced or a full refund will be given. The customer must notify ImmuQuest within 30 days after the goods have been received to request a replacement, forwarding complete test data as requested by ImmuQuest.

If items are ordered incorrectly by the customer, ImmuQuest will consider taking them back as long as they have been stored correctly and have not been opened or tampered with. Such orders may be subject to a 15% restocking charge on the items plus any shipping costs.

Requests for returns must have prior authorization from ImmuQuest, and must be made within 7 days of receipt of the items. Items must be returned in the same or equivalent packaging as originally dispatched, and by an equivalent method of delivery.

If you have any questions please contact us using the following details:

ImmuQuest Ltd
Springboard
Stokesley Business Park
24 Ellerbeck Way
Stokesley
TS9 5JZ
UK

Tel: 01642 713533
Fax: 01642 713988
International Tel: +44 1642 713533
International Fax: +44 1642 713988

When placing an order ImmuQuest require a purchase order number, plus name and contact details of the purchaser, and the person who will be using the product. ImmuQuest will also need a VAT number for customers in the European Union.UK customers that are VAT exempt need to fax an exemption certificate.

Orders can be placed either by our website, via email or by mail. Please see our contact us page for more details. All orders are subject to availability. Prices of products do not include shipping, VAT or import duties where these are applicable.

Price and other information provided are subject to change without notice. While every effort is made to keep information provided Up to date, ImmuQuest will not be liable if errors should occur in such information. Formal acceptance of an order will take place when the goods are dispatched. If prices should be changed between the time of receipt of an order and dispatch, ImmuQuest will contact you in advance.